Proprietary CDMS platform — from eCRF to statistical analysis.

Explore · 72%

Our French specialist in clinical biometrics & data management — and the cornerstone of the Oxurion platform.

Oxurion/Investors/News/ThromboGenics Reports Initial Data from its Clinical Stud…

ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-317 for the Treatment of Diabetic Macular Edema (DME)

4 Apr 2018General

Oxurion (Euronext Brussels: OXUR) is a Belgian company building a leading European group of clinical research organizations.

OXUR · EURONEXT BRUSSELS€0.0034

0.00%·3 Jun 2026

Oxurion NV
Gaston Geenslaan 1
B-3001 Leuven
Belgium

info@oxurion.com
+32 16 75 13 10